Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.47 +1.2%	$2.58	$1.60 ▼ $17.55	$66.87M	2.16	378,962 shs	134,668 shs
CLSD Clearside Biomedical	$0.87 +2.4%	$0.88	$0.70 ▼ $1.65	$66.85M	2.04	346,173 shs	76,389 shs
LPTX Leap Therapeutics	$0.42 +8.0%	$0.38	$0.22 ▼ $4.79	$17.25M	0.22	827,287 shs	1.49 million shs
PYRGF PyroGenesis Canada	$0.32 -1.6%	$0.36	$0.30 ▼ $0.80	$60.23M	0.78	11,849 shs	1,000 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+1.24%	+8.88%	+5.86%	-42.53%	-84.32%
CLSD Clearside Biomedical	+1.38%	+5.56%	-11.11%	-8.18%	-34.53%
LPTX Leap Therapeutics	-2.10%	+0.34%	+22.33%	-32.24%	-87.38%
PYRGF PyroGenesis Canada	-5.20%	-1.50%	-8.89%	-15.90%	-10.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.8393 of 5 stars	3.3	2.0	0.0	0.0	1.6	0.0	0.6
CLSD Clearside Biomedical	2.0751 of 5 stars	3.5	3.0	0.0	0.0	2.1	1.7	0.0
LPTX Leap Therapeutics	2.4515 of 5 stars	3.1	4.0	0.0	0.0	2.7	0.0	1.3
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$15.40	523.48% Upside
CLSD Clearside Biomedical	3.00	Buy	$5.25	506.87% Upside
LPTX Leap Therapeutics	2.25	Hold	$4.92	1,075.95% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LPTX, ANRO, PYRGF, and CLSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/31/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/28/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/27/2025	LPTX Leap Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/21/2025	ANRO Alto Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/6/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/6/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	$1.66M	40.18	N/A	N/A	($0.25) per share	-3.46
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$2.35 per share	N/A
PYRGF PyroGenesis Canada	$9.14M	6.59	N/A	N/A	($0.01) per share	-32.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$36.31M	-$2.54	N/A	N/A	N/A	N/A	-49.28%	-33.52%	5/13/2025 (Estimated)
CLSD Clearside Biomedical	-$32.49M	-$0.47	N/A	N/A	N/A	-413.83%	N/A	-92.90%	5/8/2025 (Estimated)
LPTX Leap Therapeutics	-$81.41M	-$1.84	N/A	N/A	N/A	N/A	-116.24%	-93.18%	5/12/2025 (Estimated)
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Latest LPTX, ANRO, PYRGF, and CLSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.20 million	N/A
3/27/2025	Q4 2024	CLSD Clearside Biomedical	-$0.13	-$0.10	+$0.03	-$0.10	$0.27 million	$0.31 million
3/26/2025	Q4 2024	LPTX Leap Therapeutics	-$0.39	-$0.37	+$0.02	-$0.37	N/A	N/A
3/20/2025	Q4 2024	ANRO Alto Neuroscience	-$0.65	-$0.56	+$0.09	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.05	13.10	13.09
CLSD Clearside Biomedical	N/A	4.49	4.49
LPTX Leap Therapeutics	N/A	3.97	3.97
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CLSD Clearside Biomedical	18.75%
LPTX Leap Therapeutics	30.46%
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
CLSD Clearside Biomedical	9.20%
LPTX Leap Therapeutics	5.40%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
CLSD Clearside Biomedical	30	77.28 million	68.87 million	Optionable
LPTX Leap Therapeutics	40	41.26 million	36.25 million	Optionable
PYRGF PyroGenesis Canada	90	186.69 million	96.34 million	No Data

LPTX, ANRO, PYRGF, and CLSD Headlines

Recent News About These Companies

PyroGenesis Canada (NASDAQ:PYRGF) Trading Up 1.4% - Still a Buy?

April 19, 2025 | marketbeat.com

P. Peter Pascali Updates Early Warning Report

April 10, 2025 | globenewswire.com

PyroGenesis Inc. (PYRGF) Q4 2024 Earnings Call Transcript

April 1, 2025 | seekingalpha.com

PyroGenesis Announces Fourth Quarter and Full Year 2024 Results

March 31, 2025 | globenewswire.com

PyroGenesis Schedules 2024 Fiscal Year Financial Results and Business Update Conference Call

March 26, 2025 | globenewswire.com

PyroGenesis Inc.: PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | finanznachrichten.de

PyroGenesis Provides Update on Varennes Carbon Recycling Project

March 21, 2025 | globenewswire.com

HPQ’s Statement on U.S. - Canada Tariff Situation, Reinforces Case for Domestic Fumed Silica Production

March 12, 2025 | markets.businessinsider.com

PyroGenesis and GE Vernova Sign Memorandum of Understanding (MOU)

March 11, 2025 | globenewswire.com

PyroGenesis Provides Response to Impact of U.S. Tariffs

March 4, 2025 | globenewswire.com

PyroGenesis in final stages of Boeing supplier qualification for course titanium powder

March 4, 2025 | pm-review.com

PyroGenesis Improves Key Performance Parameters of its NexGenTM Plasma Atomized Metal Powder Production System

March 4, 2025 | markets.businessinsider.com

Technical Requirements for Titanium Coarse Metal Powder Have Been Met by PyroGenesis' NexGen™ Plasma Atomized Metal Powder for Global Aerospace OEM

March 3, 2025 | globenewswire.com

PyroGenesis Announces First Material Produced from Fumed Silica Reactor

February 27, 2025 | globenewswire.com

PyroGenesis signs plasma torch contract with Norsk Hydro

February 24, 2025 | msn.com

PyroGenesis Signs $2.4 Million Contract with Norsk Hydro ASA

February 24, 2025 | markets.businessinsider.com

PyroGenesis signs second biogas contract with global leader

February 18, 2025 | msn.com

PFAS Destruction Testing Confirms That PyroGenesis’ Plasma Torches Reduce Energy Requirements By Up To 45%

February 10, 2025 | markets.businessinsider.com

PFAS Destruction Testing Confirms That PyroGenesis' Plasma Torches Reduce Energy Requirements By Up To 45%

February 10, 2025 | globenewswire.com

PyroGenesis Provides Update on Impact of Potential U.S. Tariffs

February 4, 2025 | globenewswire.com

Contract Increase for Reducing Greenhouse Gases Sending Shares Higher

February 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, ANRO, PYRGF, and CLSD Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.47 +0.03 (+1.23%)

As of 03:58 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Clearside Biomedical NASDAQ:CLSD

$0.87 +0.02 (+2.44%)

As of 04:00 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Leap Therapeutics NASDAQ:LPTX

$0.42 +0.03 (+7.95%)

As of 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

PyroGenesis Canada NASDAQ:PYRGF

$0.32 -0.01 (-1.65%)

As of 02:32 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time